Shares of BioDelivery Sciences International, Inc. (NASDAQ:BDSI) have earned a consensus rating of “Buy” from the ten ratings firms that are presently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $6.80.

Several equities research analysts have recently commented on BDSI shares. TheStreet raised BioDelivery Sciences International from a “d” rating to a “c” rating in a report on Friday, November 22nd. Janney Montgomery Scott reissued a “buy” rating on shares of BioDelivery Sciences International in a research note on Wednesday, November 13th. BidaskClub raised BioDelivery Sciences International from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 16th. William Blair restated a “buy” rating on shares of BioDelivery Sciences International in a report on Tuesday, September 17th. Finally, LADENBURG THALM/SH SH upped their price objective on shares of BioDelivery Sciences International from $6.00 to $8.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th.

In other news, Director Mark A. Sirgo sold 24,506 shares of the company’s stock in a transaction on Thursday, September 19th. The shares were sold at an average price of $4.79, for a total value of $117,383.74. Following the transaction, the director now directly owns 1,874,637 shares of the company’s stock, valued at $8,979,511.23. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Mark A. Sirgo sold 157,177 shares of the company’s stock in a transaction on Tuesday, September 17th. The stock was sold at an average price of $4.79, for a total transaction of $752,877.83. Following the completion of the transaction, the director now directly owns 1,874,637 shares in the company, valued at $8,979,511.23. The disclosure for this sale can be found here. In the last ninety days, insiders sold 4,420,189 shares of company stock valued at $26,074,576. 8.94% of the stock is currently owned by insiders.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Russell Investments Group Ltd. lifted its stake in BioDelivery Sciences International by 3.8% in the third quarter. Russell Investments Group Ltd. now owns 86,390 shares of the specialty pharmaceutical company’s stock valued at $365,000 after acquiring an additional 3,160 shares during the last quarter. Rhumbline Advisers boosted its stake in shares of BioDelivery Sciences International by 4.6% during the 3rd quarter. Rhumbline Advisers now owns 87,670 shares of the specialty pharmaceutical company’s stock worth $369,000 after acquiring an additional 3,851 shares in the last quarter. California State Teachers Retirement System boosted its stake in shares of BioDelivery Sciences International by 3.7% during the 3rd quarter. California State Teachers Retirement System now owns 130,150 shares of the specialty pharmaceutical company’s stock worth $548,000 after acquiring an additional 4,587 shares in the last quarter. Cutter & CO Brokerage Inc. acquired a new position in shares of BioDelivery Sciences International during the 2nd quarter valued at about $60,000. Finally, NEXT Financial Group Inc increased its holdings in shares of BioDelivery Sciences International by 17.0% during the 2nd quarter. NEXT Financial Group Inc now owns 135,350 shares of the specialty pharmaceutical company’s stock valued at $629,000 after acquiring an additional 19,700 shares during the last quarter. 69.44% of the stock is owned by hedge funds and other institutional investors.

BioDelivery Sciences International stock traded down $0.05 during midday trading on Friday, hitting $6.71. The company’s stock had a trading volume of 56,439 shares, compared to its average volume of 1,720,447. BioDelivery Sciences International has a 12 month low of $2.80 and a 12 month high of $7.01. The company has a quick ratio of 2.02, a current ratio of 2.25 and a debt-to-equity ratio of 0.86. The company has a market capitalization of $605.16 million, a PE ratio of -9.21 and a beta of 0.49. The stock’s 50-day moving average price is $5.91 and its 200-day moving average price is $4.74.

BioDelivery Sciences International (NASDAQ:BDSI) last released its earnings results on Tuesday, November 12th. The specialty pharmaceutical company reported $0.33 EPS for the quarter, topping analysts’ consensus estimates of ($0.01) by $0.34. The business had revenue of $30.31 million for the quarter, compared to the consensus estimate of $28.86 million. BioDelivery Sciences International had a negative net margin of 22.11% and a negative return on equity of 8.80%. As a group, equities analysts anticipate that BioDelivery Sciences International will post 0.02 EPS for the current year.

BioDelivery Sciences International Company Profile

BioDelivery Sciences International, Inc, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies.

Featured Story: Do closed-end mutual funds pay dividends?

Analyst Recommendations for BioDelivery Sciences International (NASDAQ:BDSI)

Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.